Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

The mum-of-two claims it was only after repeat visits and tests over the ensuing months that she was finally diagnosed with stage four classical Hodgkin lymphoma in October last year. Rebecca ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of progression-free (PFS) and overall survival (OS) at 3-5 years ...

Lymphocyte-predominant Hodgkin's lymphoma (LPHL) is a rare disease, which differs substantially from classical Hodgkin's lymphoma (cHL) with regard to histopathology and clinical course.

Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

Yescarta continued to demonstrate durable responses after a median follow-up of more than five years in patients with R/R indolent non-Hodgkin lymphoma. Treatment with the CAR-T cell therapy Yescarta ...